Propagermanium administration for patients with type 2 diabetes and nephropathy: A randomized pilot trial

Summary Aims We assessed the potential efficacy and safety of propagermanium (PG), an organic compound that inhibits the C–C chemokine receptor type 2, administration in patients with type 2 diabetes and nephropathy. Furthermore, we assessed the feasibility of future studies. Materials and methods W...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Akinori Hara, Miho Shimizu, Erika Hamaguchi, Hirokazu Kakuda, Kenzo Ikeda, Toshiya Okumura, Kiyoki Kitagawa, Yoshitaka Koshino, Motoo Kobayashi, Kazuya Takasawa, Yukimasa Hisada, Tadashi Toyama, Yasunori Iwata, Norihiko Sakai, Takashi Wada
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Wiley 2020-07-01
Serie:	Endocrinology, Diabetes & Metabolism
Ämnen:	albuminuria CCR2 diabetes kidney MCP‐1 propagermanium
Länkar:	https://doi.org/10.1002/edm2.159
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!